



OPEN ACCESS

EDITED BY

Vsevolod V. Gurevich,
Vanderbilt University, United States

REVIEWED BY

Brian Hudson,
University of Glasgow, United Kingdom
Natasha L. Grimsey,
the University of Auckland, New Zealand

*CORRESPONDENCE

Erick M. Carreira,
✉ erickm.carreira@org.chem.ethz.ch
David A. Sykes,
✉ david.sykes@nottingham.ac.uk
Dmitry B. Veprintsev,
✉ dmitry.veprintsev@nottingham.ac.uk

[†]These authors have contributed equally to this work

RECEIVED 24 July 2024

ACCEPTED 11 February 2025

PUBLISHED 09 April 2025

CITATION

Borrega-Roman L, Hoare BL, Kosar M, Sarott RC, Patej KJ, Bouma J, Scott-Dennis M, Koers EJ, Gazzi T, Mach L, Barrondo S, Sallés J, Guba W, Kuszniir E, Nazaré M, Rufer AC, Grether U, Heitman LH, Carreira EM, Sykes DA and Veprintsev DB (2025) A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay. *Front. Pharmacol.* 16:1469986. doi: 10.3389/fphar.2025.1469986

COPYRIGHT

© 2025 Borrega-Roman, Hoare, Kosar, Sarott, Patej, Bouma, Scott-Dennis, Koers, Gazzi, Mach, Barrondo, Sallés, Guba, Kuszniir, Nazaré, Rufer, Grether, Heitman, Carreira, Sykes and Veprintsev. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay

Leire Borrega-Roman^{1,2,3,4†}, Bradley L. Hoare^{1,2†}, Miroslav Kosar⁵, Roman C. Sarott⁵, Kacper J. Patej⁵, Jara Bouma⁶, Morgan Scott-Dennis^{1,2}, Eline J. Koers^{1,2}, Thais Gazzi⁷, Leonard Mach⁷, Sergio Barrondo^{3,4,8}, Joan Sallés^{3,4,8}, Wolfgang Guba⁹, Eric Kuszniir⁹, Marc Nazaré⁷, Arne C. Rufer⁹, Uwe Grether⁹, Laura H. Heitman⁶, Erick M. Carreira^{5*}, David A. Sykes^{1,2*} and Dmitry B. Veprintsev^{1,2*}

¹Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom, ²Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom, ³Department of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain, ⁴Bioaraba, Neurofarmacologia Celular y Molecular, Vitoria-Gasteiz, Spain, ⁵Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland, ⁶Division of Drug Discovery and Safety, Leiden Academic Center for Drug Research, Leiden University and Oncode Institute, Leiden, Netherlands, ⁷Leibniz-Forschungsinstitut für Molekulare Pharmakologie FMP, Campus BerlinBuch, Berlin, Germany, ⁸Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain, ⁹Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

Introduction: The kinetics of ligand binding to G protein-coupled receptors (GPCRs) is an important optimization parameter in drug discovery. Traditional radioligand assays are labor-intensive, preventing their application at the early stages of drug discovery. Fluorescence-based assays offer several advantages, including a possibility to develop a homogeneous format, continuous data collection, and higher throughput. This study sought to develop a fluorescence-based binding assay to investigate ligand-binding kinetics at human cannabinoid type 1 and 2 receptors (CB1R and CB2R).

Methods: We synthesized D77, a novel tracer derived from the non-selective cannabinoid Δ^8 -THC. Using time-resolved Förster resonance energy transfer (TR-FRET), we developed an assay to study ligand-binding kinetics at physiological temperatures. For CB1R, we truncated the first 90 amino acids of its flexible N-terminal domain to reduce the FRET distance between the terbium cryptate (donor) and the fluorescent ligand (acceptor). The full-length CB2R construct was functional without modification due to its shorter N-terminus. The Motulsky–Mahan competition binding model was used to analyze the binding kinetics of the endocannabinoids and several other non-fluorescent ligands.

Results: The D77 tracer showed nanomolar-range affinity for truncated CB1R (CB1R_{91–472}) and full-length CB2R (CB2R_{1–360}), displaying competitive binding with orthosteric ligands. D77 exhibited rapid dissociation kinetics from both CB1R and CB2R, which were similar to the fastest dissociating reference compounds. This was critical for accurately determining the on- and off-rates of the fastest

dissociating compounds. Using D77, we measured the kinetic binding properties of various CB1R and CB2R agonists and antagonists at physiological temperature and sodium ion concentration.

Discussion: The k_{on} values for molecules binding to CB1R varied by three orders of magnitude, from the slowest (HU308) to the fastest (rimonabant). A strong correlation between k_{on} and affinity was observed for compounds binding to CB1R, indicating that the association rate primarily determines their affinity for CB1R. Unlike CB1R, a stronger correlation was found between the dissociation rate constant k_{off} and the affinity for CB2R, suggesting that both k_{on} and k_{off} dictate the overall affinity for CB2R. Exploring the kinetic parameters of cannabinoid drug candidates could help drug development programs targeting these receptors.

KEYWORDS

time-resolved Forster resonance energy transfer- based binding assay, fluorescent ligand, kinetic ligand binding assay, cannabinoid type 1, cannabinoid type 2, cannabinoid receptors, rebinding, ligand depletion

Introduction

Cannabinoid type 1 and 2 receptors (CB1R and CB2R) are essential signaling elements of the endocannabinoid system. They belong to the G protein-coupled receptor (GPCR) family and show different distribution patterns in the human body. The CB1R is predominantly expressed in the central nervous system (CNS) (Katona et al., 1999), but it is also found in peripheral organs, including adipose tissue, the liver, and the pancreas, where it is involved in the regulation of metabolic functions (Pacher et al., 2006; Han and Kim, 2021). The CB2R is primarily expressed in peripheral tissues related to the immune system (Khurana et al., 2017), such as the spleen and thymus (Munro et al., 1993; Galiègue et al., 2005), but it is also found in the CNS, although expressed at much lower levels compared to CB1R. Efforts to develop drugs targeting CB1R have primarily focused on their roles in neuromodulation and metabolic regulation, particularly in obesity treatment, while CB2R has been explored for its ability to regulate inflammatory processes and immune-related disorders (Aso and Ferrer, 2016; Kaur et al., 2016; Vuic et al., 2022), with further potential to treat or ameliorate certain neurodegenerative disorders (Navarro et al., 2016; An et al., 2020; Bala et al., 2024).

Phytocannabinoids, such as extracts of the plant *Cannabis sativa*, have been used in traditional medicine for millennia (Zuardi, 2006; Zuardi, 2008). Even though the cannabinoid system has been considered a promising intervention point for a plethora of diseases (Di Marzo, 2018; Maccarrone et al., 2023), very few drugs targeting CB1R or CB2R have reached the clinic to date. Currently, dronabinol and nabilone are the only Food and Drug Administration (FDA)-approved synthetic cannabinoids, which are Δ^9 -THC or close derivatives. These are non-selective compounds used for treating nausea and anorexia, which are the outcomes of cancer chemotherapy treatments. One example of a selective CB1R ligand is the antagonist rimonabant, which was marketed as an effective anti-obesity drug. However, it was subsequently withdrawn from the market due to its adverse neuropsychiatric effects (Moreira and Crippa, 2009).

Difficulties in targeting CB1R and CB2R for therapeutic benefit can be partly explained by their wide distribution in the body and their role as modulators of multiple processes that are primarily

driven by other signaling cascades. Designing selective drug candidates with optimal pharmacological properties requires addressing multiple challenges, including receptor-binding kinetics. Although affinity measures are useful, they often fail to fully capture the complexities of drug-receptor interaction. Incorporating kinetic parameters, such as residence time, into the early stages of drug discovery offers valuable insights into drug efficacy, rebinding, and off-target toxicity. This understanding plays a crucial role in enhancing rational drug design (Fuchs et al., 2000; Casarosa et al., 2009; Tresadern et al., 2011; Fleck et al., 2012; Sykes et al., 2012; Guo et al., 2016; Sykes et al., 2017; Sykes et al., 2022). Ligand-receptor kinetic studies also enable better predictions of drug-receptor coverage *in vivo*, which in turn leads to improved therapeutic outcomes (Copeland, 2016; Vauquelin, 2016). Even though our understanding of cannabinoid receptor pharmacology has dramatically increased during the last few decades, the binding kinetics of compounds acting on either of these receptor subtypes under physiologically relevant conditions remain largely unexplored.

Traditionally, drug-receptor binding properties have been investigated by means of radiolabeled ligands, with excellent progress in developing selective ligands for CB2R (Dowling and Charlton, 2009; Sykes et al., 2010; Ramsey et al., 2011; Martella et al., 2017; Soethoudt et al., 2018). However, these methods are very labor-intensive and present many limitations such as lower throughput, the risk associated with the handling of hazardous radioactive material, the increased time and costs incurred by these experimental procedures, and the inability to study rapid binding events (Martella et al., 2017; Xia et al., 2017; Xia et al., 2018; Georgi et al., 2019; Sykes et al., 2019). An important consideration for such filtration-based radioligand binding assays is that the tracer itself must possess a relatively slow-off rate from the receptor of interest so that the effective separation of bound and unbound radioligands is achievable during the washing stage. However, in order to quantify the kinetic parameters of typical CB2R selective ligands, which display fast dissociation kinetics, the tracer itself must also display comparably fast dissociation kinetics (Sykes et al., 2019). Another disadvantage of using radioligands is the higher levels of background signals exhibited by certain probes, even when they possess high affinity for the primary target. The use

of fluorescence-based methods and resonance energy transfer, in particular, has helped revolutionize the study of ligand binding to GPCRs, with the main advantage being the lower levels of non-specific signals due to the requirement for proximity between the donor and acceptor in the generation of the specific binding signal (Sykes et al., 2019; Soave et al., 2020). An additional benefit of fluorescence-based time-resolved Förster resonance energy transfer (TR-FRET) assays is that they are homogenous and do not require the separation of bound and unbound ligands. Kinetic binding assays using labeled tracer ligands can also be used to determine the on/off rates of unlabeled ligands at the receptor (Motulsky and Mahan, 1984), provided that the kinetics of the tracer binding are suitable (Sykes et al., 2019). During the course of this work, another group reported the use of TR-FRET binding assays for CB1R and CB2R using a proprietary fluorescent ligand (Raich et al., 2021; Navarro et al., 2023); however, only equilibrium data were presented, so it is unclear if this probe would be suitable for profiling the kinetic properties of low-affinity rapidly dissociating compounds.

Herein, we report a homogeneous TR-FRET competitive association binding assay using the novel fluorophore D77, a nitrobenzoxadiazole (NBD)-labeled tracer, based on the pharmacophore embedded in Δ^8 -THC. The use of this tracer allowed us to characterize CB1R and CB2R ligand kinetic parameters (association rate constant k_{on} and dissociation rate constant k_{off}) at 37°C using the kinetic model of drug-receptor competition binding proposed by Motulsky and Mahan (1984). Using a set of reference compounds for CB1R and CB2R, we present a robust method to perform high-throughput *in vitro* screening of cannabinoid compounds to assess both their affinity and ligand-binding kinetics and explore the basis of selectivity between these two main cannabinoid receptors.

Materials and methods

Materials

T-REx™-293 (Invitrogen) cells were obtained from Thermo Fisher Scientific. Culture flasks T75 and T175 cm² were purchased from Thermo Fisher Scientific. DMEM (high glucose) and Dulbecco's phosphate-buffered saline (DPBS), with no calcium and magnesium (D8537), were purchased from Sigma-Aldrich. Cellstripper™ was purchased from Corning. Hanks' Balanced Salt solution (H8264), HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), EDTA (ethylenediaminetetraacetic acid), bovine serum albumin (BSA) heat shock fraction, protease-free, fatty acid-free, essentially globulin-free (A7030), poly-D-lysine, tetracycline, and Pluronic F127 were purchased from Sigma-Aldrich. The transfection reagent PEI Linear, MW 25000, transfection-grade (PEI 25K) was obtained from Polysciences (23966-1). The selection reagents blasticidin, geneticin (G418), and zeocin were obtained from Invitrogen. A bicinchoninic acid (BCA)-based protein assay kit (Pierce™ BCA Protein Assay Kit) used to determine the total protein content of membranes was obtained from Thermo Fisher Scientific. 2-AG, AEA, rimonabant, SR 144528, HU-308, and HU-210 were obtained from Tocris Bioscience (United Kingdom). CP 55,940 was obtained from

Sigma-Aldrich. All ligands were dissolved in 100% DMSO and stored as aliquots at −20°C until required. Dimethyl sulfoxide (DMSO, 276855) was purchased from Sigma-Aldrich. OptiPlate-384 (white opaque 384-well microplate) was purchased from PerkinElmer (Beaconsfield, United Kingdom).

Plasmid constructs: cloning and preparation

Plasmid constructs for human CB1R and CB2R have been reported previously (Heydenreich et al., 2017; Hoare et al., 2024). Constructs were in pcDNA4/TO, with a preceding cleaved signal peptide (5HT3A; to target the receptor with an extracellular SNAP tag to the ER for correct membrane incorporation and biogenesis), followed by a Twin-Strep affinity tag, a SNAP tag, and the receptor sequence. To produce the truncated CB1R construct, a PCR-based Gibson assembly method (Heydenreich et al., 2017) was used to remove the relevant nucleotide sequence. All plasmid constructs were verified through the entirety of the coding sequence via Sanger sequencing. Both CB1R and CB2R coding sequences were the canonical human isoform (UniProt ID #P21554-1 for CB1R and #P34972 for CB2R). Plasmid DNA was prepared using standard bacterial expression methods and purified using column-based extraction kits from QIAGEN.

Cell culture and membrane preparation

T-REx™-293 cells were cultured in T75 and T175 flasks in DMEM (high glucose) supplemented with 10% FBS and blasticidin (10 µg/mL; to maintain the selection pressure for the pcDNA6/TR plasmid, which represses constitutive expression from the CMV promoter of pcDNA4/TO). Cells have been tested for *mycoplasma* using the MycoAlert® PLUS *Mycoplasma* Detection Kit (Lonza). Passage numbers were kept below 20. To generate stable cell lines expressing SNAP-tagged receptors, T-REx™-293 cells were transfected with pcDNA4/TO constructs using PEI and selected with zeocin (20 µg/mL) for 14 days to obtain an antibiotic-resistant cell population with plasmid expression.

T-REx™-293 cells stably expressing either SNAP-CB1R₉₁₋₄₇₂ or SNAP-CB2 were cultured in T175 flasks using DMEM supplemented with 10% fetal bovine serum. Tetracycline (1 µg/mL) was added to the culture 48 h prior to labeling to induce receptor expression. When the cells reached 90%–100% confluency, the medium was removed, and the cells were washed using 10 mL of PBS, followed by 10 mL Tag-lite labeling medium (LABMED, Cisbio). Finally, 10 mL of LABMED containing 100 nM of SNAP-Lumi4-Tb was added and incubated for 1 h at 37°C under 5% CO₂. After removing the labeling solution, PBS was used to wash the cells, which were dissociated using non-enzymatic dissociation buffer. Cells were centrifuged for 5 min (350 × g), and pellets were kept at −80°C until membranes were prepared.

For membrane preparation, all steps were conducted at 4°C to avoid tissue degradation. Cells pellets were thawed and resuspended using ice-cold buffer containing 10 mM HEPES and 10 mM EDTA at pH 7.4. The suspension was homogenized using an electrical homogenizer ULTRA-TURRAX (Ika-Werk GmbH, Germany) and subsequently centrifuged at 1,200 × g for 5 min. The pellet obtained

containing the cell nucleus and other heavy organelles was discarded, and the supernatant was centrifuged for 30 min at $48,000 \times g$ at 4°C (Beckman Avanti J-251 ultracentrifuge; Beckman Coulter). The supernatant was discarded, and the pellet was resuspended using the same buffer (10 mM HEPES and 10 mM EDTA, pH 7.4) and centrifuged a second time for 30 min as described above. Finally, the supernatant was discarded, and the pellet was resuspended using ice-cold 10 mM HEPES and 0.1 mM EDTA at pH 7.4. Protein concentration determination was carried out using the Pierce[™] BCA Protein Assay Kit (Thermo Fisher) and using BSA as a standard. The final membrane suspension was aliquoted and maintained at -80°C until required for the assays.

Common procedures used in TR-FRET experiments

Experiments were performed using T-REx[™]-293 cell membranes expressing SNAP-tagged human CB1R or CB2R (SNAP-CB1R_{91–472} and SNAP-CB2). All the assays were conducted at either 25°C or 37°C in white 384-well OptiPlate plates (PerkinElmer) using the PHERAstar FSX microplate reader (BMG Labtech). The TRF 337/620/520 optic module was used for all assays, except for tracer MKA-136, where the TRF 337/570/490 module was utilized. Each well was excited with four laser flashes, and signal detection was performed with a 100- μs delay, integrating the signal over 700 μs .

Assay buffer comprised HBSS (Hanks' Balanced Salt Solution) containing 5 mM HEPES, 0.5% BSA, and 0.02% Pluronic F-127 at pH 7.4. BSA (0.5%) and 0.02% Pluronic F-127 were used to minimize the non-specific binding of hydrophobic compounds to plasticware. Membranes were preincubated with 100 μM of GppNHP at 25 or 37°C for 15 min prior to addition to the plate using automatic injectors to ensure early time points could be measured with accuracy. GppNHP is a non-hydrolyzable GTP analog that will bind to G proteins and promote the dissociation of G proteins from the receptor. This way, we promote a single population of receptors (uncoupled from G proteins) avoiding a mixed population (i.e., uncoupled receptors (R) and receptors coupled to GDP bound G proteins, or G proteins alone (RG)). Adding GTP analogs is a common strategy used in GPCR binding studies to ensure a homogeneous single-state receptor population and simplify the analysis.

To control for potential plate position effects, plate layouts were varied between independent experiments. Non-specific (NS) signals at CB1R and CB2R were determined in the presence of saturating concentrations of rimonabant (3 μM) and SR 144528 (1 μM), respectively. D77 stock was prepared at 100x the final concentration, and 0.4 μL was added to the wells. DMSO was held constant at 2% for all assay points, including the saturation and competition binding experiments, as reflected in the text.

Saturation binding studies

Fluorescent ligand binding to CB1R and CB2R was assessed by homogeneous time-resolved FRET (HTRF) detection, allowing the construction of saturation binding curves. For fluorescent ligand

characterization, six concentrations of D77 were chosen ranging from 31.25 to 1,000 nM. Cell membranes containing human CB1R or CB2R (1 $\mu\text{g}/\text{well}$) were added (at $t = 0$) to the wells in a total volume of 40 μL containing 2% DMSO at 25 or 37°C , with gentle agitation. The non-specific (NS) signal was determined in the presence of saturating concentrations of either rimonabant (3 μM) or SR 144528 (1 μM). The resulting data were fitted to the one-site model equation (Equation 1) to derive a single best-fit estimate for K_d , as described under *Data analysis*. The receptor concentration in our assay was calculated to be 150–300 pM based on a terbium standard curve (see Supplementary Figure S1). This ensures that ligand depletion to the receptor is minimal as significant depletion will occur when the receptor concentration approaches or exceeds the free ligand concentration and is near its K_d . Ligand depletion is considered significant when more than 10% of the ligand is bound (Motulsky and Neubig, 2002), which, in this case would require nmol-range high-affinity binding sites per μg of protein (assuming negligible non-specific binding in the assay).

One inherent limitation of a 384-well fluorescent ligand binding assay format is the inability to accurately measure ligand depletion. Although the affinity of the tracer used in this study is relatively low, it is crucial to ensure that ligand depletion does not significantly impact the assay, particularly given the small reaction volumes used. The addition of BSA and Pluronic F-127 to the assay buffer minimizes ligand adsorption to the plate surface. The fluorescence intensity of different fluorescent ligand concentrations can be measured to assess this practically, and should be a linear relationship. To further assess potential issues, one approach is to verify that the Hill coefficient of the ligand-binding equilibrium saturation binding curve, when plotted in logarithmic units and fitted to a sigmoidal model, is close to 1 (Carter et al., 2007). Another strategy involves centrifuging the reaction mixture to separate membrane-bound components and confirming that residual fluorescence remains unchanged, helping identify substantial non-specific membrane binding (Hulme, 1999). These considerations are recommended when working with higher-affinity tracers to ensure the validity of binding models that assume equivalence between total and free ligand concentrations.

Determination of affinity constants (K_i)

To obtain affinity estimates of the unlabeled ligand, D77 competition experiments were performed at equilibrium. D77 was used at a concentration of 600 nM and 900 nM in binding assays for CB1R or CB2R, respectively. D77 was incubated in the presence of the indicated concentration of the unlabeled ligand and CB1 and CB2R cell membranes (1 $\mu\text{g}/\text{well}$) in a total volume of 40 μL containing 2% DMSO at 25 or 37°C , with gentle agitation. The non-specific (NS) signal was determined in the presence of saturating concentrations of either rimonabant (3 μM) or SR 144528 (1 μM). Steady-state competition curves were obtained following a 15-min incubation period, and data were fitted using GraphPad Prism 9.2 to the one site competition binding model (Equation 2) to calculate the IC_{50} values, which were converted to K_i values by applying the Cheng–Prusoff correction as described under *Data analysis*.

Determination of the association rate (k_{on}) and dissociation rate (k_{off}) of fluorescent ligands

Fluorescent ligand binding to CB1R and CB2R was assessed via HTRF detection, allowing the construction of association binding curves. For fluorescent ligand characterization, six increasing concentrations of fluorescent ligands were prepared, and cell membranes containing human CB1R or CB2R (1 μ g/well) were added (at $t = 0$) in a total volume of 40 μ L containing 2% DMSO at 25 or 37°C, with gentle agitation. Non-specific (NS) signals were determined in the presence of saturating concentrations of either rimonabant (3 μ M) or SR 144528 (1 μ M). As the wells are read sequentially, we restricted the readout of kinetic data of two ligands per experimental run to reduce the minimum reading cycle time. The wells were read every 8 s during a 15-min period, and the resulting data were globally fitted to the association kinetic model (Equation 3) to derive a single best-fit estimate for K_d , k_{on} , and k_{off} as described under *Data analysis*.

Competition binding kinetics

Competitive kinetic association experiments were carried out using the D77 fluorescent ligand as a tracer. Cell membranes containing the human CB1R or CB2R (1 μ g/well) were added (at $t = 0$) to wells containing D77 and the unlabeled compound to white 384-well OptiPlates in a total volume of 40 μ L containing 2% DMSO at 25 or 37°C, with gentle agitation. The concentrations of the tracer used in the experiments were 600 nM and 900 nM for CB1R and CB2R, respectively, which avoid ligand depletion in the volume mentioned above. Concentrations of D77 were selected just above its K_d for CB1R, taking into account the kinetic properties of the tracer that dictate the time to equilibrium. In this case, using 600 nM allows for a fast equilibrium for the application of the Motulsky and Mahan model. In the case of CB2R, we decided to choose a higher concentration ($\sim 2.5 \times K_d$) in order to compensate for its slower k_{on} and lower specific binding HTRF signal. By using 900 nM, we could improve our assay window and accelerate k_{obs} , which is a function of the ligand concentration used ($k_{obs} = k_{on}[L] + k_{off}$).

The degree of D77 bound to the receptor was assessed every 8 s over a 15-min period. Non-specific (NS) signals were determined in the presence of saturating concentrations of either rimonabant (3 μ M) or SR 144528 (1 μ M) and was subtracted from each timepoint. Rimonabant and SR 144528 concentrations used to define NSB were chosen based on the measured pK_d values of 4.6 nM and 2.82 nM, respectively. These concentrations are $>300 \times$ the respective K_d of each ligand and lead to $>99.7\%$ of receptor occupation ($\% \text{ Occupied} = ([L]/([L] + K_d) \times 100)$). Therefore, the concentrations were chosen to efficiently block fluorescent ligand binding while not causing more general physical changes to the membrane that might alter specific binding.

The association of the D77 was monitored using TR-FRET in competition with 8 different concentrations of each cannabinoid ligand. The resulting data were globally fitted in GraphPad Prism 9.2 to the “kinetics of competitive binding” model (Equation 4) to derive a single best-fit estimate of K_d , k_{on} , and k_{off} for different cannabinoid compounds as described under *Data analysis*.

Synthesis of fluorescent probes

The structures (see [Supplementary Figure S6](#)) and details of synthetic procedures, as well as compound characterizations, can be found in [Supplementary Information](#).

Material availability

The D77 compound, receptor constructs, and associated cell lines are not commercially available. However, detailed methods for their generation and use are provided within the manuscript.

Data analysis

Data are expressed in the text and tables as mean $\pm$ SEM for the indicated number of experiments. All experiments were analyzed by non-linear regression using Prism 9.2 (GraphPad Software, San Diego, United States).

Saturation binding

D77 total and non-specific (NS) signal data were analyzed via non-linear regression according to one-site binding equations, and individual estimates for maximal specific binding (B_{max}) and ligand dissociation constant (K_d) were calculated. The following one-site model equation was used, where $[A]$ is the concentration of the ligand:

$$\text{Specific} = \frac{B_{max}[A]}{K_d + [A]} \quad (1)$$

$$NS = \text{slope}[A] + \text{background}$$

Competition binding

Steady-state competition displacement binding data were fitted to sigmoidal (variable slope) curves using a “four parameter logistic equation:”

$$Y = \text{Bottom} + \frac{(\text{Top} - \text{Bottom})}{1 + 10^{(\log IC_{50} - X) * \text{Hillslope}}} \quad (2)$$

where Bottom and Top represent the lower and upper plateaus of the specific binding signal, respectively. $\log IC_{50}$ is the logarithm of the competitor concentration that displaces 50% of the bound fluorescent tracer, and the Hill slope is the unitless slope factor. IC_{50} values obtained from the competition curves were converted to K_i values using the method of [Cheng and Prusoff \(1973\)](#).

Association binding

D77 association data were fitted to a global fitting model using GraphPad Prism 9.2 to simultaneously calculate k_{on} and k_{off} using the following equation, where k_{obs} equals the observed rate of association and L is the concentration of D77:




FIGURE 1

Truncation of human cannabinoid receptor type 1 (CB1R) allows for specific TR-FRET binding signals from fluorescent tracers. (A) Diagram showing how the long N-terminal domain (NTD) of CB1R (111 amino acids) may preclude FRET between the terbium cryptate donor and fluorescent tracer and rationale for truncating to shorten the distance. (B) Amino acid sequence of the N-terminal of human CB1R and its splicing variants hCB1a and hCB1b. The highlighted amino acids represent the N-terminal sequence of the truncated CB1R versions used (91–472 in dark blue and 55–472 in light blue), modified from Ryberg et al. (2005). (C) Total, non-specific (NS), and specific TR-FRET binding signals at full-length and truncated CB1R obtained using NBD-691 (1 μ M).

$$k_{obs} = [L] \cdot k_{on} + k_{off} \quad (3)$$

Competition kinetic binding

The association rate k_{on} and the dissociation rate k_{off} calculated for different cannabinoid compounds were obtained by global fitting of competition binding data using the model “kinetics of competitive binding” in GraphPad Prism 9.2:

$$\begin{aligned} K_A &= k_1[L] + k_2K_B = k_3[I] + k_4 \\ S &= \sqrt{((K_A - K_A)^2 + 4 \cdot k_1 \cdot k_3 \cdot L \cdot I \cdot 10^{-18})} \\ K_F &= 0.5 \cdot (K_A + K_B + S)K_S = 0.5 \cdot (K_A + K_B - S) \\ Q &= \frac{B_{max} \cdot K_1 \cdot L \cdot 10^{-9}}{K_F - K_S} \\ Y &= Q \cdot \left(\frac{k_4 \cdot (K_F - K_S)}{K_F \cdot K_S} + \frac{k_4 - K_F}{K_F} \exp^{(-K_F \cdot X)} - \frac{k_4 \cdot K_S}{K_S} \exp^{(-K_S \cdot X)} \right) \end{aligned} \quad (4)$$

where X is the time (min), Y is the specific binding (HTRF units 520 nm/620 nm*10,000), k_1 is the k_{on} of the tracer D77, k_2 is the k_{off} of the tracer D77, L is the concentration of D77 used (nM), and I is

the concentration of the unlabeled agonist (nM). Fixing the abovementioned parameters allowed the following to be simultaneously calculated: B_{max} is the total binding (HTRF units 520 nm/620 nm*10,000), k_3 is the association rate of the unlabeled ligand ($M^{-1} \min^{-1}$) or k_{on} , and k_4 is the dissociation rate of the unlabeled ligand ($\min^{-1}$) or k_{off} .


Linear correlations

The correlation between datasets was determined by calculating the Pearson correlation coefficient (presented as the r^2 coefficient of determination, which shows percentage variation in y , which is explained by all the x variables together) in GraphPad Prism 9.2.

Results

Developing a TR-FRET binding assay for SNAP-CB1R required truncation of the N-terminus

We have previously developed a TR-FRET-based binding assay for human CB2R using a genetically encoded SNAP-tag at the N-terminus of the full-length CB2R along with complementary



fluorescent probes (Sarott et al., 2020; Gazzi et al., 2022; Kosar et al., 2023). Although these compounds showed good selectivity for CB2R, as measured in radioligand binding assays, they also bound CB1R, albeit with reduced affinity. However, we found that we could not obtain a TR-FRET signal for CB1R.

We hypothesized that the 111-amino acid residue long N-terminus of CB1R, as opposed to the 33-residue short N-terminus of CB2R, places the SNAP-Lumi4 donor too far from the fluorescent ligand bound in the orthosteric binding site (Figure 1A) for efficient FRET, at a distance of approximately 60–70 Å (or 6–7 nm). We, therefore, truncated the CB1 N-terminus to place the SNAP tag closer to the binding pocket. The truncation site was rationally chosen based on the knowledge of reported CB1R splicing variants, which have modified N-terminal domains (NTD) and retain functionality (Xiao et al., 2008). Two truncated CB1R variants were produced and named based on the residues remaining after truncation—CB1R_{55–472} and CB1R_{91–472} (Figure 1B), both containing an N-terminal SNAP tag for terbium cryptate labeling. In TR-FRET experiments, which tested for specific binding of the non-selective cannabinoid tracer NBD-691 (1 μM), only the most truncated receptor, CB1R_{91–472}, displayed a specific TR-FRET signal that is indicative of ligand binding (Figure 1C). More details on NBD-691 can be found in the Supplementary File.



Truncated receptor retains cell-surface localization and functionality

Earlier reports suggested that the N-terminal domain of the CB1R may be playing a role in receptor trafficking and stability (Hebert-Chatelain et al., 2016; Fletcher-Jones et al., 2020). In our case, we found that truncated CB1R was still detectably expressed at the cell surface when transiently expressed in HEK293T cells (see Supplementary Methods). Most likely, the signal peptide derived from the 5HT_{3A} receptor and the SNAP tag (a large extracellular folded protein domain) ensured trafficking of the engineered receptor to the cell surface (see Supplementary Figure S2).

Few studies have specifically investigated the role of the NTD of CB1R in influencing its pharmacological properties. Earlier findings suggested that the N-terminus might play a role in binding and signaling for certain endogenous ligands (Ryberg et al., 2005); however, these results have been contradicted by a more recent study reporting no functional differences between splice variants with varying N-terminal lengths (Xiao et al., 2008). To clarify this question, a comprehensive pharmacological comparison of the truncated and full-length CB1R was conducted to assess the impact of NTD truncation on receptor function (i.e., the removal of the first 90 amino acids, CB1R_{91–472}). Radioligand binding studies with the tritiated synthetic cannabinoid CP 55,940 (see Supplementary Methods) strongly suggest that CB1R truncation had no substantial effects on synthetic cannabinoid binding (see Supplementary Figure S3; Supplementary Table S1). In addition, the functional effects of the synthetic cannabinoid HU-210 and the endocannabinoids 2-AG and AEA were indistinguishable between truncated and native receptors when tested in intact cells expressing a Gi-CASE activation biosensor (Schihada et al., 2021; Scott-Dennis et al., 2023). This suggests that neither the efficacy (intrinsic activity) nor the potency of the synthetic cannabinoids nor endocannabinoids was affected by truncation of the CB1R (see Supplementary Figure S4; Supplementary Table S2).

Previously developed fluorescent tracers are too slow or too fast for measurements of ligand-binding kinetics

The binding kinetic profile (the association rate k_{on} and the dissociation rate k_{off}) of the tracer molecule will significantly influence the performance of the Motulsky and Mahan model (Georgi et al., 2019; Sykes et al., 2019). A previously developed tracer based on HU-308, MKA-115, exhibited a slow rate of association to both CB1R and CB2R. Since fast association is desired to observe competition with the cold compounds at the very earliest time points, MKA-115 was not suitable for use (see Figure 2). In addition, MKA-115 failed to reach equilibrium in the



15-min data collection period, meaning that reliable kinetic parameters could not be obtained for this tracer. NBD-691, on the other hand, was binding too fast to CB1R, for its binding kinetics to be measurable by the plate reader. In total, 10 tracers were designed, synthesized, and tested (see Supplementary Figures S5, S6; Supplementary Table S3). The design of our tracers was inspired by a reverse-design approach (Guberman et al., 2022), where known CBR ligands with varied affinity and selectivity toward CB1R and CB2R were used. The ligands were functionalized with alkyl and PEG linkers and different fluorophores to achieve optimal affinity and signal-to-noise ratio with the terbium FRET donor. This process led us to a promising lead—a Δ^8 -THC core with an NBD fluorophore. Precise structural modifications, such as choosing the lipophilic n-heptyl tail of D77 over the n-pentyl tail of MKA-136, enabled candidate D77 to exhibit an ideal profile for our intended application as a universal CBR tracer. Most tracers exhibit significant limitations, such as signal instability caused by photobleaching or an excessively rapid association phase due to very fast k_{off} values, which result in the ligand binding reaching equilibrium almost instantaneously. In contrast, D77 demonstrated a moderately rapid k_{off} enabling the observation of the association phase before equilibrium. This is critical as the Motulsky and Mahan model depends on the

competitive interaction of cold (non-fluorescent) ligands during the tracer's association phase.

Synthesis of tracer D77 (NBD- Δ^8 -THC)

Our goal of designing a universal fluorescent probe to determine the pharmacology of CBR specific ligands necessitated the identification of a pharmacophore with balanced affinity for both CB1R and CB2R. In addition, the determination of kinetic parameters of lower-affinity CBR specific ligands, such as the endocannabinoids, necessitates the use of a rapidly dissociating tracer. These criteria are in contrast to our previously reported highly CB2R-selective fluorescent probes (Sarott et al., 2020; Kosar et al., 2024). Δ^8 -THC fulfills this criterion and exhibits good affinity for both CB1R and CB2R, providing an ideal starting point for our studies (Soethoudt et al., 2017). Phenol modification is well-known to sharply reduce the affinity of THC derivatives for CB1R and was thus unsuitable for linker attachment for our purposes (Compton et al., 2002). In contrast, chemical probes based on the THC scaffold,

TABLE 1 Affinity values and kinetic parameters k_{on} and k_{off} of the D77 fluorescent tracer at 37°C. Values are calculated from kinetic association experiments and saturation experiments performed at equilibrium. Data shown are mean $\pm$ SEM of four experiments conducted independently.

	pK_d	Equilibrium pK_d
CB1R	6.36 ± 0.02	6.37 ± 0.02
CB2R	6.48 ± 0.03	6.43 ± 0.04
	k_{on} ($M^{-1} \text{ min}^{-1}$)	k_{off} (min^{-1})
CB1R	$(4.31 \pm 0.19) \times 10^6$	1.87 ± 0.05
CB2R	$(3.46 \pm 0.22) \times 10^6$	1.13 ± 0.06

as well as the available SAR data, indicate THC carbon 11 (C(11)) is a suitable locus for attachment of linkers extending into the extracellular matrix, thereby providing a sound basis for the incorporation of fluorophores (Thakur et al., 2005; Papahatjis et al., 2006; Muppidi et al., 2018). We have previously shown the requirement for minimally six carbon atoms to reach the extracellular space, as well as the pharmacological superiority of C(11) amide-over-ester linkages in cannabinoid–fluorophore conjugates, both considerations being accounted for in our design of the FRET tracer D77 (Westphal et al., 2020). Additionally, D77 harbors a C(3) n-heptyl chain, which has recently been shown to enhance the affinity for both CB1 and CB2R when compared to the n-pentyl side chain in THC (Citti et al., 2019). As a fluorescent moiety, we have chosen nitrobenzoxadiazole (NBD). Although NBD has a lower extinction coefficient (ca $20,000 \text{ cm}^{-1}M^{-1}$) and quantum yield (ca 0.4) (Uchiyama et al., 2003) than dyes like fluorescein ($65,000 \text{ cm}^{-1}M^{-1}$, 0.98), it has been proven to be a good acceptor for the terbium cryptate Lumi4 donor in our hands (Kosar et al., 2023).

The modular synthetic strategy and the structure of our universal cannabinoid receptor probe D77 are shown in Figure 3 with the synthetic methodology described in Supplementary Scheme S1. Once D77 was identified as a suitable tracer, a novel convergent synthetic approach was designed and optimized, starting from commercially available spherophorol, to access D77 in three steps with 34% overall yield (Supplementary Scheme S2). This dramatically simplified the synthesis of D77 (3 vs. 14 steps) and increased the yield of the synthesis from <1% to 34%. The new streamlined and highly efficient synthesis pathway enables a steady supply of the D77 tracer for screening purposes. D77 was characterized, and its identity was confirmed via 1H NMR, ^{13}C NMR, IR, and MS. The purity of D77 was assessed via 1H NMR and UV–Vis (254 nm and 480 nm) (see Supplementary Material). Purity of D77 was >95% across all the analytical tests conducted.

Characterization of the saturation binding of D77 to CB1R and CB2R

Saturation binding experiments with increasing concentrations of D77 were carried out in order to determine the affinity of D77 for the two cannabinoid receptor subtypes. Measurements at steady-state, obtained 5 min after ligand addition, were used as an endpoint

to obtain an equilibrium affinity measurement, or K_d value at each receptor (see Figure 4). Notably, the level of non-specific binding signals was low at both receptors, representing less than 25% of the total binding signal in both cases. Consequently, D77 achieves a relatively high level of specific binding, making it a useful tracer for competition studies and a practical alternative to the high-affinity, agonist radioligands used in the past, which are routinely employed in the absence of guanine nucleotides to preserve more specific binding. Equilibrium binding affinity values for D77 binding to the two CBR subtypes are reported in Table 1. To assess the potential for ligand depletion, we have replotted the saturation curves on a log scale and refitted the data using a four-parameter logistic equation to determine the Hill coefficient (see Supplementary Figure S7). The resulting Hill slopes were close to unity, indicating that no ligand depletion occurred under the assay conditions employed.

Equilibrium competition experiments using D77

Equilibrium competition experiments allowed us to calculate the equilibrium dissociation constant (or pK_i values) of our test set of cannabinoid compounds under equilibrium conditions. To achieve this aim, binding of D77 to CB1R and CB2R was monitored using TR-FRET in the presence of increasing concentrations of cannabinoid ligands, and IC_{50} parameters were obtained from the derived curves, as shown in Figure 5. The Cheng–Prusoff conversion equation was used to calculate K_i values from the IC_{50} values derived from these inhibitory curves, and these values expressed as negative logarithms can be found in Table 2. Generally, the pK_i values obtained using D77 were in good agreement with the literature (Govaerts et al., 2004; Khajehali et al., 2015; Martella et al., 2017; Soethoudt et al., 2017). The values obtained in this study for endogenous ligands 2-AG or AEA were somewhat lower compared to those reported by Soethoudt et al. (2017), but were comparable with the aggregated results collected by multiple laboratories (reviewed in Carruthers and Grimsey, 2023) for CB2R. A possible source of the variation in the reported values is the chemical instability of the 2-AG or AEA, which are degraded by enzymes naturally present in the cell membranes, as well as variations in the assays, where the high-affinity state caused by the G protein binding was retained or specifically dissociated by the addition of GTP analogs.

Kinetics of the association of D77 binding CB1R and CB2R

We measured the real-time association of the fluorescent tracer D77 to both cannabinoid receptor subtypes at 37°C over a period of 5 min using TR-FRET. D77 showed a rapid association profile to both CB1R and CB2R, reaching equilibrium within the first 2 min (see Figure 6).

As shown in Figures 6A, B, D77 shows optimal binding characteristics at CB1R and CB2R, making it an ideal tracer for the Motulsky and Mahan approach, which is used to determine the kinetics of unlabeled compounds binding these receptors. D77 shows a relatively fast association profile ($k_{obs} = (k_{on} \times L) +$




TABLE 2 Equilibrium dissociation constant of the cannabinoid ligands tested expressed as pK_i at 37°C. The data shown are mean $\pm$ SEM from four experiments conducted independently in singlet.

	pK_i	
	CB1R	CB2R
Rimonabant	8.98 ± 0.05	6.00 ± 0.02
HU-210	7.99 ± 0.01	9.56 ± 0.09
CP 55,940	7.51 ± 0.03	8.32 ± 0.04
2-AG	5.15 ± 0.26	5.81 ± 0.03
Anandamide	5.59 ± 0.04	6.11 ± 0.02
HU-308	5.41 ± 0.02	7.57 ± 0.03
SR 144528	6.43 ± 0.01	8.55 ± 0.05

k_{off}), yet it still allows the accurate determination of the associating phase prior to equilibrium, which is necessary for the application of the competitive association binding model (see Figures 6A, B). The association rate constants measured for D77 were relatively slow at both receptors (k_{on} -CB1R= $(4.3 \pm 0.2) \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$; k_{on} -CB2R = $(3.5 \pm 0.2) \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$). However, D77 exhibits fast dissociation rate constants at both cannabinoid receptors, with k_{off} values of $1.87 \pm 0.05 \text{ min}^{-1}$ and $1.13 \pm 0.06 \text{ min}^{-1}$ being obtained at CB1R and CB2R, respectively, meaning equilibrium between the receptor and tracer is achieved rapidly at both receptor subtypes.

Moreover, the specific binding signal of D77 remains constant over time, and we do not observe any decay in the signal due to signal bleaching within the time frame of data acquisition. The affinity values obtained from saturation equilibrium experiments were in good agreement with the kinetic K_d values determined using the kinetic approach (where, $K_d = k_{off}/k_{on}$) (Table 1), demonstrating the reliability of the tracer kinetic model fitting.

As shown in Figure 6C, the observed associated rate (k_{obs}) increases linearly with fluorescent ligand concentrations, demonstrating the expected relationship for a reversible

bimolecular binding interaction (Motulsky and Christopoulos, 2004). The extrapolation of the fitted line to $Y = 0$ yields to an estimation of k_{off} values of 2.53 min^{-1} and 1.43 min^{-1} at CB1R and CB2R, respectively, and the slope indicates a k_{on} value at a CB1R of $3.03 \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$ and at a CB2R of $2.60 \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$. These values are in good agreement with those obtained from global fitting of the D77 association binding curves (see Table 1).

Competition association binding

Having characterized the kinetics of D77 binding to CB1R and CB2R, we then evaluated its use as a tracer for the determination of the kinetics of unlabeled cannabinoid receptor ligands. The competition between the unlabeled compounds and D77 resulted in a concentration-dependent inhibition of D77 tracer binding in both the case of CB1R (see Figure 7) and CB2R (see Figure 8). The HU-210 competition curves exhibit the characteristic overshoot phenomenon, observed when the tracer first binds the receptor and then is displaced by the competitor. This reveals the slow dissociation profile of the competitor compound, HU-210, relative to the tracer. This effect was more prominent in the case of CB2R due an apostrophe to HU-210's much slower rate of dissociation at this receptor subtype, relative to the tracer (see Figures 7B, 8B). The majority of the competition association curves show a gradual increase in D77 binding, indicating faster dissociation of the competing compounds, apart from SR 144528 binding the CB2R. As shown in Tables 3, 4, we report the kinetic association and dissociation rate constants (k_{on} and k_{off}) and residence times ($Rt = 1/k_{off}$) of the unlabeled agonists and antagonists binding to both CB1R and CB2R.

For CB1R, the fastest associating compounds were rimonabant, HU-210, and CP 55,940, displaying k_{on} values of 5 , 3.8 , and $1.5 \times 10^8 \text{ M}^{-1} \text{ min}^{-1}$, respectively, followed by SR 144528 ($k_{on} = 1.4 \times 10^7 \text{ M}^{-1} \text{ min}^{-1}$). The two endocannabinoid compounds 2-AG and AEA showed similar slower association rate constants ($k_{on} = 1.4$ and $2.4 \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$, respectively). The compound with slowest




FIGURE 6

Determination of D77 kinetic binding parameters at 37°C. Association binding curves obtained from six concentrations of the fluorescent ligand D77 are shown for (A) CB1R and (B) CB2R. Kinetic experiments derive a K_d value for the D77 ligand of 437 ± 22 nM for CB1R and 370 ± 16 nM for CB2R. The observed association rate constant (k_{obs}) obtained for each concentration of fluorescent tracer D77 fitted to a linear regression model (C). Binding followed a simple law of mass action model, and k_{obs} increasing in a linear manner with fluorescent ligand concentration. Data are presented as representative graphs (A, B) or mean $\pm$ SEM (C) from four experiments conducted independently.

association was a CB2R selective binder, HU-308, with a k_{on} value of 6.6×10^5 M⁻¹ min⁻¹, which is consistent with its lower affinity for CB1R.

Regarding the dissociation profile of the compounds at CB1R, the fastest dissociating compounds were 2-AG, CP 55,940, AEA, and SR 144528, therefore displaying the shortest residence times at this receptor subtype of ~ 10 s. HU-210 exhibited the longest residence time (slowest k_{off}) of 71 s, followed by the inverse agonist rimonabant (Rt = 27 s) and HU-308 (Rt = 21 s).

The competition binding approach has revealed a remarkably small difference between the kinetic dissociation parameters of these ligands, with only the agonist HU-210 displaying a relatively slow off-rate from the CB1R compared to the rapidly dissociating tracer D77 and the endocannabinoid agonists AEA and 2-AG.

For CB2R, the fastest associating compounds were CP 55,940, HU-210, and SR 144528, displaying k_{on} values of 4.4, 2.6, and 2.5×10^8 M⁻¹ min⁻¹, respectively, followed by HU-308, which displayed a k_{on} value of 5.6×10^7 M⁻¹ min⁻¹. The two endocannabinoid compounds 2-AG and AEA showed similar slower association rate constants (k_{on} 1.2×10^7 and 9.7×10^6 M⁻¹ min⁻¹, respectively), similar to rimonabant (k_{on} of 9.2×10^6 M⁻¹ min⁻¹).

Regarding the dissociation profile of the compounds, those with fastest dissociation were 2-AG, rimonabant, and AEA, therefore displaying the shortest CB2R residence times of ~ 4 s (2-AG) and ~ 10 s (both rimonabant and AEA). CP 55,940, HU-308, and SR 144528 exhibited slower dissociation rates, with residence times of 33 s, 40 s, and 87 s, respectively. By far, the compound with slowest dissociation was HU-210, with a residence time of 20 min.

Competitive association binding experiments using the D77 tracer were performed at 25°C, and the resulting k_{on} , k_{off} , and pK_d values for both CB1R and CB2R are provided in [Supplementary Tables S4, S5](#). As expected, the association and dissociation rates at 25°C were slower than those observed at 37°C ([Tables 3, 4](#)). Of note, the temperature effect varied across the tested compounds, leading to a different rank order for some of them. For example, at CB1R, rimonabant exhibited the longer residence time at 25°C (171 s), followed by HU-210 (160 s), whereas at 37°C, HU-210 was the compound displaying the longest residence time (71 s), followed by rimonabant (27 s).

Kinetic parameters correlate differently for CB1R and CB2R

The equilibrium dissociation constants for the tested cannabinoid compounds were calculated from the kinetic association and dissociation rates from kinetic experiments (kinetic K_d ; $K_d = k_{off}/k_{on}$) and from the equilibrium displacement data (K_i). Both values were compared for the binding of the compounds to both CB1R and CB2R. As shown in [Figure 9](#), the kinetic K_d affinity values generated showed a strong correlation with the K_i values obtained from the equilibrium displacement binding; Pearson correlation coefficients (r) of 0.97 ($P = 0.0004$) and 0.99 ($P < 0.0001$) were obtained at CB1R and CB2R, respectively. These results show that the association and dissociation rates obtained from the association competition experiments are consistent with




FIGURE 7
Competition kinetic binding curves of cannabinoid ligands at 37°C competing with D77 for CB1R. Experiments were conducted using a fixed concentration of the tracer molecule D77 (600 nM) and increasing concentrations of unlabeled ligands (A) rimonabant, (B) HU-210, (C) CP 55,940, (D) 2-AG, (E) anandamide (AEA), (F) HU-308, and (G) SR 144528. Data were globally fitted to the competition association model using GraphPad Prism 9.2 to simultaneously calculate k_{on} and k_{off} values of the unlabeled competitors. Graphs show competition association curves from a single experiment representative of ≥ 3 experiments conducted independently.

the affinity values obtained from equilibrium competition data, validating our approach using the tracer D77.

We performed a correlation analysis using the kinetic parameters (k_{on} and k_{off}) versus affinity values obtained for our test set of compounds, in order to explore the role of association and dissociation constant rates in dictating the affinity of the ligands for CB1R and CB2R.

The affinities and association rates of compounds show a strong correlation at both CB1R and CB2R when performing a correlation analysis of their logarithmic transformations (pK_d vs. $\log k_{on}$), whereas the dissociation rates, expressed as negative logarithmic transformations, are only significantly correlated with ligand affinity values for CB2R (see Figure 10). These results suggest that k_{on} , the association rate constant rather than k_{off} , the dissociation rate constant, is the biggest determinant of receptor affinity for CB1R,

whereas both k_{on} and k_{off} parameters dictate the affinity for CB2R binding. The correlation between the affinity and dissociation rates for the CB2R, found with the selected compounds in this study, contrasts with the results published previously with a different set of CB2R binding compounds (Martella et al., 2017), where no significant correlation was reported between affinity and k_{off} values.

Discussion

In this study, we aimed to develop a fluorescent ligand binding assay for profiling the kinetic parameters of compounds binding to the orthosteric binding sites of CB1R and CB2R. The motivation for this was to advance on the existing radioligand binding techniques currently available for this purpose.





TABLE 3 Kinetic parameters calculated from the Motulsky and Mahan experimental approach for the cannabinoid compounds tested at CB1R at 37°C. The data shown are mean $\pm$ SEM from four experiments conducted independently (except for 2-AG, where N = 3).

CB1R (37°C)	k_{on} (M ⁻¹ min ⁻¹)	k_{off} (min ⁻¹)	Residence time (Rt)		pK _d
			(min)	(s)	
Rimonabant	(5.03 $\pm$ 0.54) $\times 10^8$	2.23 $\pm$ 0.14	0.45 $\pm$ 0.03	27 $\pm$ 2	8.35 $\pm$ 0.06
HU-210	(3.79 $\pm$ 0.10) $\times 10^8$	0.85 $\pm$ 0.02	1.18 $\pm$ 0.03	71 $\pm$ 2	8.65 $\pm$ 0.01
CP 55,940	(1.54 $\pm$ 0.10) $\times 10^8$	5.63 $\pm$ 0.34	0.18 $\pm$ 0.01	11 $\pm$ 1	7.44 $\pm$ 0.03
2-AG	(1.40 $\pm$ 0.47) $\times 10^6$	6.74 $\pm$ 0.44	0.15 $\pm$ 0.01	9.0 $\pm$ 0.5	5.27 $\pm$ 0.15
Anandamide	(2.39 $\pm$ 0.46) $\times 10^6$	5.37 $\pm$ 0.63	0.19 $\pm$ 0.02	12 $\pm$ 1	5.64 $\pm$ 0.03
HU-308	(6.61 $\pm$ 0.81) $\times 10^5$	2.98 $\pm$ 0.35	0.35 $\pm$ 0.04	21 $\pm$ 2	5.35 $\pm$ 0.01
SR 144528	(1.35 $\pm$ 0.24) $\times 10^7$	4.99 $\pm$ 0.73	0.21 $\pm$ 0.03	13 $\pm$ 2	6.43 $\pm$ 0.01

TABLE 4 Kinetic parameters calculated from the Motulsky and Mahan experimental approach for the cannabinoid compounds tested for CB2R at 37°C. Data are expressed as the mean ± SEM of four experiments conducted independently.

CB2R (37°C)	k_{on} (M ⁻¹ min ⁻¹)	k_{off} (min ⁻¹)	Residence time (Rt)		p <i>K</i> _d
			(min)	(s)	
Rimonabant	(9.20 ± 1.25) × 10 ⁶	6.37 ± 0.75	0.16 ± 0.02	10 ± 1	6.15 ± 0.03
HU-210	(2.62 ± 0.24) × 10 ⁸	(5.1 ± 0.29) × 10 ⁻²	19.84 ± 1.13	1,190 ± 67	9.71 ± 0.05
CP 55,940	(4.38 ± 0.48) × 10 ⁸	1.85 ± 0.14	0.55 ± 0.04	33 ± 3	8.37 ± 0.02
2-AG	(1.21 ± 0.18) × 10 ⁷	(1.44 ± 0.18) × 10 ¹	0.07 ± 0.01	4.4 ± 0.7	5.92 ± 0.04
Anandamide	(9.69 ± 0.37) × 10 ⁶	6.15 ± 0.66	0.17 ± 0.02	10 ± 1	6.20 ± 0.04
HU-308	(5.58 ± 0.34) × 10 ⁷	1.53 ± 0.09	0.66 ± 0.04	40 ± 2	7.56 ± 0.02
SR 144528	(2.47 ± 0.16) × 10 ⁸	0.69 ± 0.03	1.46 ± 0.07	87 ± 4	8.55 ± 0.03



Development of TR-FRET ligand-binding assay for cannabinoid receptors

Previously, we reported a TR-FRET ligand binding assay for CB2R (Sarott et al., 2020; Gazzi et al., 2022). In this study, we adapted the assay format for CB1R using genetic engineering to introduce an SNAP-tag to incorporate the donor, terbium cryptate. This ensured that our assay reported binding to only the overexpressed receptor subtype, avoiding tracer specificity issues seen in the radioligand binding assay. TR-FRET is a well-established approach, but it is often underappreciated as it only reports a signal based on proximity, providing ultimate assay specificity irrespective of the selectivity of the tracer employed. This improves the specific/non-specific signal ratio compared to traditional radioligand binding assays, where all ligands remaining after filtration contributes to the total signal, including the ligand which remains bound to unspecific sites of the cell membrane, or the filters themselves.

However, for CB1R, the truncation of the N-terminus was necessary to shorten the donor–acceptor distance and facilitate the FRET, a process

we recently successfully employed to profile high-affinity fluorescent probes binding to CB1R (Mach et al., 2024). Although there is always a consideration that any receptor modification may affect its biogenesis, ligand binding, or signaling properties, our imaging, binding, and functional data strongly suggest that the distal N-terminal residues are not in any way impacting the trafficking or binding/activation capability of the receptor (see Supplementary Figures S2–S4). This same truncation strategy could be applied to develop fluorescent ligand binding assays for other receptors that have an exceptionally long N-terminus.

During our research, another group published TR-FRET equilibrium assays using full-length SNAP-tagged CB1R in combination with a proprietary red fluorescent ligand called CELT-335, which was also used for CB2R (Raich et al., 2021). In comparison, our own fluorescent ligands did not yield a TR-FRET binding signal at the full-length SNAP-CB1R. The reason for this discrepancy is most likely due to differences in the fluorescent tracer used, both in terms of the linker (and hence how the conjugated fluorescent acceptor moiety may be positioned relative to the terbium




FIGURE 10

Correlation plots of equilibrium and kinetic parameters of cannabinoid compounds at CB1R and CB2R. Correlation between negative logarithmic transformation of affinities ($-\log K_d$) and logarithmic (A) association rate ($\log k_{on}$) and (B) dissociation rate ($\log k_{off}$) for CB1R ligands. Correlation between negative logarithmic transformation of affinities ($-\log K_d$) and logarithmic (C) association rates ($\log k_{on}$) and (D) dissociation rates ($\log k_{off}$) for CB2R ligands. Correlation analysis was carried out using a Pearson correlation analysis (two-tailed). Data shown are the mean and SEM of four independent experiments.

donor on the SNAP tag) and the spectral properties of the fluorophore. CELT-335 is presumably a relatively bright fluorophore with the excitation/emission peaks of 646 nm and 662 nm, respectively (Navarro et al., 2023), whereas NBD (D77's fluorophore) has excitation/emission peaks at 467 nm and 538 nm, respectively, and is relatively "dim." The Förster radius (R_0 ; the distance at which FRET efficiency is 50%) between a given donor and acceptor pairing is heavily influenced by the length of the linker and the properties of the acceptor fluorophore (Chen et al., 2006; Braslavsky et al., 2008), such as its molar extinction coefficient (ϵ) and the overlap between donor emission and acceptor absorbance (Chen et al., 2006; Braslavsky et al., 2008). These factors could account for a difference in R_0 between the terbium cryptate donor and either the D77 or CELT-335 fluorophores, which would allow FRET for the full-length CB1R:CELT335 pairing but not the full-length CB1R:D77 pairing.

D77 is an excellent fluorescent tracer for equilibrium ligand binding to CB1 and CB2

Our secondary aim was to develop a kinetically fast fluorescent ligand that would serve as an ideal tracer to profile other compounds binding to CB1R and CB2R. In order to achieve this aim, we synthesized and developed D77, a fluorescent derivative of Δ^8 -THC, as an optimal fluorescent tracer for cannabinoid receptors.

D77 performed extremely well in terms of its ability to accurately measure the affinity of the non-fluorescent competitor compounds. Given its ease of use and our ability to scale up the testing throughput, through use of a commonly available plate reader with injectors and TR-FRET capability, this assay employing D77 effectively replaces radioligand binding assays previously employed to screen for ligands binding to cannabinoid receptors.

Fluorescent tracer D77 applicability to kinetic studies

Crucially, D77, based on Δ^8 -THC, has a balanced affinity for both CBR subtypes, and it exhibits a more rapid k_{off} over the previously described CB2R tracers (Sarott et al., 2020; Gazzi et al., 2022; Kosar et al., 2023; Kosar et al., 2024). This improves the assay performance and allows more accurate and precise estimates of the kinetic parameters of more rapidly dissociating compounds (Georgi et al., 2019; Sykes et al., 2019).

The kinetic parameters for a number of compounds obtained with D77 are similar to those obtained earlier at CB2R using a radioligand kinetic binding assay at 25°C (Martella et al., 2017), where they reported similar residence times (CP 55,940: 5 min; HU-308: 4.2 min; SR 144,528: 8.7 min; AEA: 1.4 min; and 2-AG: 0.31 min) to those in our study (CP 55,940: 3.2 min; HU-308:




FIGURE 11

Consequences of rebinding on the apparent reversal of CB1R occupancy in the brain and periphery. Simulated target reversal rates were derived under conditions of limited diffusion based on the association (k_{on}) and dissociation (k_{off}) rates determined in competition kinetic binding experiments. All kinetic parameters used for these plots are taken from Table 3. For simulation purposes, the reversal rate k_r was based on the model of an immunological synapse (Coombs and Goldstein, 2004). k_r values are calculated using the following equation $k_r = k_{off}/(1 + k_{on} \cdot [R]/k_-)$, where k_{off} is the dissociation rate from the receptor, k_{on} is the association rate onto the receptor, $[R]$ is the surface receptor density fixed at $1 \times 10^{11} \text{ cm}^{-2}$ for CB1R calculations, and k_- is the diffusion rate of the synaptic compartment into bulk aqueous, fixed at $1.2 \times 10^{-5} \text{ cm/s}$.

2.7 min; SR 144,528: 6.3 min; AEA: 0.8 min; and 2-AG: 0.5 min). Of note, D77 served our interest of developing an assay capable of determining the kinetic parameters of unlabeled ligands at physiological temperature. Moreover, the use of injectors overcomes the challenge of working at 37°C, which necessitates the collection of early time points, due to the fast association and dissociation rates observed for both the tracer D77 and the tested ligands.

Measuring kinetic parameters of cannabinoid ligands at physiological temperature creates opportunities for improving compound efficacy under conditions of limited diffusion

We successfully determined the kinetic binding parameters of seven different reference compounds binding to CB1R and CB2R. The kinetic parameters determined at 25°C (see Supplementary Tables S4, S5) and 37°C (see Tables 3, 4) reveal important differences in the residence time of the compounds tested at CB1R and CB2R, where, for example, HU-210 displayed a much longer residence time at CB2R (over 30 min longer). These findings strongly support the development of new approaches that enable kinetic characterization of ligand–receptor binding at physiological temperatures, allowing more accurate and detailed preclinical prediction models of drug action to be formulated. For example,

if a particular receptor is mainly expressed in the brain, the prediction of drug binding in this compartment over time, through implementation of a rebinding model, will be more useful to identify optimal drug dosing (Sykes et al., 2017). In view of HU-210's rapid association and slow off rate, it is intriguing that it has been shown to exhibit a noticeably longer duration of action in preclinical animal studies (Hruba and McMahon, 2014) and thus may possess unique beneficial qualities when it comes to behavioral and neurobiological alterations, compared to THC and other cannabinoids (Farinha-Ferreira et al., 2022). In contrast, the endogenous cannabinoids exhibit slow association and a much more rapid dissociation from both receptor subtypes. The potential for rebinding to affect the pharmacodynamic properties of ligands binding to CB1R in the brain and periphery has been documented in previous publications (Vauquelin, 2016; Terry et al., 2009), and its effect on apparent receptor reversal of the endogenous agonist 2-AG and the synthetic agonist HU-210 is illustrated in Figure 11. Under conditions of high receptor density and limited diffusion, such as those found in the synaptic environment of the brain, we can expect HU-210, which possesses a relatively rapid association rate, to occupy receptors for much longer than in the periphery, where diffusion occurs more freely. In contrast, under identical conditions, the endogenous ligand 2-AG, which has a much slower association rate and more rapid dissociation rate, would be expected to reverse more rapidly with very little influence of receptor density or diffusion on this process.

Limitations of the study

Previous TR-FRET binding assays have been successfully developed to profile the kinetics of ligands binding GPCRs (Schiele et al., 2015; Sykes et al., 2017). One limitation of this new CB1R assay format is that the receptor needs to be truncated to incorporate the SNAP-tag at the N-terminus close to the orthosteric binding site. Indeed, fluorescent ligand binding to human CB1R has been described previously using TR-FRET and an SNAP-tagged full-length CB1R (Raïch et al., 2021); however, it is unclear if kinetic assays with the reported tracer would be feasible, as their binding kinetic parameters were not reported. Unfortunately, none of the fluorescent ligands reported in this study showed detectable signals with the full-length CB1R. Although there may be some tertiary structure present in the first 90 residues of the N-terminus, the absence of this region did not influence the pharmacology of the receptor. The second limitation is the necessity of an SNAP-tagged receptor. This effectively prevents the use of this ligand binding assay with endogenously expressed untagged receptors. Although a genetically engineered mouse model with an SNAP-tagged GLP-1 receptor has been reported (Ast et al., 2023), such models are not available for CB1R or CB2R.

Conclusion

The novel TR-FRET-based method we outline utilizing the probe D77 (a fluorescent derivate of Δ^8 -THC) constitutes a simple and superior alternative to radioligand binding methodologies to determine the equilibrium and kinetic binding of compounds for cannabinoid receptors at physiological temperature. Investigating the kinetic parameters of prospective cannabinoid drug candidates could help us identify essential factors for refining their design and lead to the discovery of more effective medicines to target these receptors.

Data availability statement

The original contributions presented in the study are included in the article/[Supplementary Material](#); further inquiries can be directed to the corresponding authors.

Author contributions

LB-R: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, validation, visualization, writing—original draft, and writing—review and editing. BH: conceptualization, data curation, formal analysis, investigation, methodology, validation, writing—original draft, and writing—review and editing. MK: data curation, formal analysis, investigation, methodology, resources, validation, visualization, and writing—review and editing. RS: data curation, investigation, methodology, resources, validation, and writing—review and editing. KP: investigation, methodology, resources, validation, visualization, and writing—review and editing. JB: visualization, writing—review and editing, data curation,

investigation, methodology, resources, and validation. MS-D: data curation, investigation, methodology, and writing—review and editing. EJK: investigation, methodology, validation, visualization, and writing—review and editing. TG: investigation, methodology, resources, and writing—review and editing. LM: investigation, methodology, resources, and writing—review and editing. SB: funding acquisition, methodology, and writing—review and editing. JS: conceptualization, funding acquisition, supervision, and writing—review and editing. WG: investigation, methodology, resources, and writing—review and editing. EK: investigation, methodology, resources, and writing—review and editing. MN: funding acquisition, methodology, resources, supervision, and writing—review and editing. AR: funding acquisition, investigation, methodology, resources, and writing—review and editing. UG: funding acquisition, investigation, methodology, resources, and writing—review and editing. LH: funding acquisition, investigation, methodology, supervision, and writing—review and editing. EC: funding acquisition, investigation, methodology, resources, supervision, and writing—review and editing. DS: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, visualization, and writing—review and editing. DV: conceptualization, formal analysis, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, visualization, and writing—review and editing.

Funding

The author(s) declare that financial support was received for the research, and/or publication of this article. LB-R is a recipient of a predoctoral grant awarded by the Department of Education of the Basque Government, a Short-Term Fellowship awarded by the European Molecular Biology Organization (EMBO) and a Short-Term Scientific Mission grant awarded by the European Research Network on Signal Transduction (ERNEST, Cost Action 18133). DBV gratefully acknowledges funding by the Swiss National Science Foundation grants 135754 and 159748 and the Novartis Foundation FreeNovation grant. EJK, DS, and DV gratefully acknowledge funding by the Medical Research Council [grant number MR/Y003667/1]. JB contribution was supported by the Dutch Research Council (NWO, Vidi #16573). LB-R, BH, JB, MS-D, EJK, LH, DS, and DV are members of COST Action CA18133 “ERNEST.” DAS and DBV gratefully acknowledge funding by F. Hoffmann-La Roche Ltd., Basel, Switzerland [Roche Postdoctoral Fellowship RPF-551]. Authors affiliated with F. Hoffmann-La Roche Ltd contributed to the study design and writing of the manuscript. The funder was not involved in data collection, analysis, interpretation, or the decision to submit the article for publication.

Conflict of interest

Authors TG, LM, and MN were employed by Campus Berlin-Buch. Authors WG, EK, AR, and UG were employed by F. Hoffmann-La Roche Ltd. DS and DV are both founders and directors of Z7 Biotech Ltd, an early-stage drug discovery CRO.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the

reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2025.1469986/full#supplementary-material>

References

- An, D., Peigneur, S., Hendrickx, L. A., and Tytgat, J. (2020). Targeting cannabinoid receptors: current status and prospects of natural products. *Int. J. Mol. Sci.* 21 (14), 5064. doi:10.3390/ijms21145064
- Aso, E., and Ferrer, I. (2016). CB2 cannabinoid receptor as potential target against alzheimer's disease. *Front. Neurosci.* 10, 243. doi:10.3389/fnins.2016.00243
- Ast, J., Nasteska, D., Fine, N. H. F., Nieves, D. J., Koszegi, Z., Lanoiselée, Y., et al. (2023). Revealing the tissue-level complexity of endogenous glucagon-like peptide-1 receptor expression and signaling. *Nat. Commun.* 14 (1), 301. doi:10.1038/s41467-022-35716-1
- Bala, K., Porel, P., and Aran, K. R. (2024). Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders. *Psychopharmacol. Berl.* 241 (10), 1939–1954. doi:10.1007/s00213-024-06683-w
- Braslavsky, S. E., Fron, E., Rodriguez, H. B., Roman, E. S., Scholes, G. D., Schweitzer, G., et al. (2008). Pitfalls and limitations in the practical use of Forster's theory of resonance energy transfer. *Photochem. and Photobiological Sci.* 7 (12), 1444–1448. doi:10.1039/b810620g
- Carruthers, E. R., and Grimsey, N. L. (2023). Cannabinoid CB2 receptor orthologues; *in vitro* function and perspectives for preclinical to clinical translation. *Br. J. Pharmacol.* 181 (14), 2247–2269. doi:10.1111/bph.16172
- Carter, C. M., Leighton-Davies, J. R., and Charlton, S. J. (2007). Miniaturized receptor binding assays: complications arising from ligand depletion. *J. Biomol. Screen* 12 (2), 255–266. doi:10.1177/1087057106297788
- Casarosa, P., Bouyssou, T., Germeyer, S., Schnapp, A., Gantner, F., and Pieper, M. (2009). Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. *J. Pharmacol. Exp. Ther.* 330 (2), 660–668. doi:10.1124/jpet.109.152470
- Chen, H., Puhl, H. L., 3rd, Koushik, S. V., Vogel, S. S., and Ikeda, S. R. (2006). Measurement of FRET efficiency and ratio of donor to acceptor concentration in living cells. *Biophys. J.* 91 (5), L39–L41. doi:10.1529/biophysj.106.088773
- Cheng, Y.-C., and Prusoff, W. H. (1973). Relationship between the inhibition constant (K₁) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. *Biochem. Pharmacol.* 22 (23), 3099–3108. doi:10.1016/0006-2952(73)90196-2
- Citti, C., Linciano, P., Russo, F., Luongo, L., Iannotta, M., Maione, S., et al. (2019). A novel phytocannabinoid isolated from *Cannabis sativa* L. with an *in vivo* cannabinimetic activity higher than Δ^9 -tetrahydrocannabinol: Δ^9 -Tetrahydrocannabinophorol. *Sci. Rep.* 9 (1), 20335. doi:10.1038/s41598-019-56785-1
- Compton, D. R., Prescott, W. R., Martin, B. R., Siegel, C., Gordon, P. M., and Razdan, R. K. (2002). Synthesis and pharmacological evaluation of ether and related analogues of delta 8-delta 9- and delta 9,11-tetrahydrocannabinol. *J. Med. Chem.* 34 (11), 3310–3316. doi:10.1021/jm00115a023
- Coombs, D., and Goldstein, B. (2004). Effects of the geometry of the immunological synapse on the delivery of effector molecules. *Biophys. J.* 87 (4), 2215–2220. doi:10.1529/biophysj.104.045674
- Copeland, R. A. (2016). Drug-target interaction kinetics: underutilized in drug optimization? *Future Med. Chem.* 8 (18), 2173–2175. doi:10.4155/fmc-2016-0183
- Di Marzo, V. (2018). New approaches and challenges to targeting the endocannabinoid system. *Nat. Rev. Drug Discov.* 17 (9), 623–639. doi:10.1038/nrd.2018.115
- Dowling, M. R., and Charlton, S. J. (2009). Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. *Br. J. Pharmacol.* 148 (7), 927–937. doi:10.1038/sj.bjp.0706819
- Farinha-Ferreira, M., Rei, N., Fonseca-Gomes, J., Miranda-Lourenço, C., Serrão, P., Vaz, S. H., et al. (2022). Unexpected short- and long-term effects of chronic adolescent HU-210 exposure on emotional behavior. *Neuropharmacology* 214, 109155. doi:10.1016/j.neuropharm.2022.109155
- Fleck, B. A., Hoare, S. R. J., Pick, R. R., Bradbury, M. J., and Grigoriadis, D. E. (2012). Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. *J. Pharmacol. Exp. Ther.* 341 (2), 518–531. doi:10.1124/jpet.111.188714
- Fletcher-Jones, A., Hildick, K. L., Evans, A. J., Nakamura, Y., Henley, J. M., and Wilkinson, K. A. (2020). Protein interactors and trafficking pathways that regulate the cannabinoid type 1 receptor (CB1R). *Front. Mol. Neurosci.* 13, 108. doi:10.3389/fnmol.2020.00108
- Fuchs, B., Breithaupt-Grögler, K., Belz, G. G., Roll, S., Malerczyk, C., Herrmann, V., et al. (2000). Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. *J. Pharm. Pharmacol.* 52 (9), 1075–1083. doi:10.1211/0022357001774994
- Galiègue, S., Mary, S., Marchand, J., Dussosoy, D., Carrière, D., Carayon, P., et al. (2005). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur. J. Biochem.* 232 (1), 54–61. doi:10.1111/j.1432-1033.1995.tb20780.x
- Gazzi, T., Brennecke, B., Atz, K., Korn, C., Sykes, D., Forn-Cuni, G., et al. (2022). Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe. *Chem. Sci.* 13 (19), 5539–5545. doi:10.1039/d1sc06659e
- Georgi, V., Dubrovskiy, A., Steigle, S., and Fernández-Montalván, A. E. (2019). Considerations for improved performance of competition association assays analysed with the Motulsky–Mahan's "kinetics of competitive binding" model. *Br. J. Pharmacol.* 176 (24), 4731–4744. doi:10.1111/bph.14841
- Govaerts, S. J., Hermans, E., and Lambert, D. M. (2004). Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. *Eur. J. Pharm. Sci.* 23 (3), 233–243. doi:10.1016/j.ejps.2004.07.013
- Guberman, M., Kosar, M., Omran, A., Carreira, E. M., Nazare, M., and Grether, U. (2022). Reverse design toward optimized labeled chemical probes - examples from the endocannabinoid system. *Chim. (Aarau)* 76 (5), 425–434. doi:10.2533/chimia.2022.425
- Guo, D., Heitman, L. H., and Ijzerman, A. P. (2016). The added value of assessing ligand-receptor binding kinetics in drug discovery. *ACS Med. Chem. Lett.* 7 (9), 819–821. doi:10.1021/acsmchemlett.6b00273
- Han, J. H., and Kim, W. (2021). Peripheral CB1R as a modulator of metabolic inflammation. *FASEB J.* 35 (4), e21232. doi:10.1096/fj.202001960R
- Hebert-Chatelain, E., Desprez, T., Serrat, R., Bellocchio, L., Soria-Gomez, E., Busquets-Garcia, A., et al. (2016). A cannabinoid link between mitochondria and memory. *Nature* 539 (7630), 555–559. doi:10.1038/nature20127
- Heydenreich, F. M., Miljuš, T., Jaussi, R., Benoit, R., Milić, D., and Veprintsev, D. B. (2017). High-throughput mutagenesis using a two-fragment PCR approach. *Sci. Rep.* 7 (1), 6787. doi:10.1038/s41598-017-07010-4
- Hoare, B. L., Tippet, D. N., Kaur, A., Cullum, S. A., Miljuš, T., Koers, E. J., et al. (2024). ThermoBRET: a ligand-engagement nanoscale thermostability assay applied to GPCRs. *Chembiochem.* 25 (2), e202300459. doi:10.1002/cbic.202300459
- Hrubá, L., and McMahon, L. R. (2014). The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys. *Eur. J. Pharmacol.* 727, 35–42. doi:10.1016/j.ejphar.2014.01.041
- Hulme, E. C. (1999). Analysis of binding data. *Methods Mol. Biol.* 106, 139–185. doi:10.1385/0-89603-530-1:139
- Katona, I., Sperlág, B., Sik, A., Kálfalvi, A., Vizi, E. S., Mackie, K., et al. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. *J. Neurosci.* 19 (11), 4544–4558. doi:10.1523/jneurosci.19-11-04544.1999
- Kaur, R., Ambwani, S. R., and Singh, S. (2016). Endocannabinoid system: a multi-facet therapeutic target. *Curr. Clin. Pharmacol.* 11 (2), 110–117. doi:10.2174/1574884711666160418105339

- Khajehali, E., Malone, D. T., Glass, M., Sexton, P. M., Christopoulos, A., and Leach, K. (2015). Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. *Mol. Pharmacol.* 88 (2), 368–379. doi:10.1124/mol.115.099192
- Khurana, L., Mackie, K., Piomelli, D., and Kendall, D. A. (2017). Modulation of CB1 cannabinoid receptor by allosteric ligands: pharmacology and therapeutic opportunities. *Neuropharmacology* 124, 3–12. doi:10.1016/j.neuropharm.2017.05.018
- Kosar, M., Sarott, R. C., Sykes, D. A., Viray, A. E. G., Vitale, R. M., Tomasevic, N., et al. (2024). Flipping the GPCR switch: structure-based development of selective cannabinoid receptor 2 inverse agonists. *ACS Cent. Sci.* 10 (5), 956–968. doi:10.1021/acscentsci.3c01461
- Kosar, M., Sykes, D. A., Viray, A. E. G., Vitale, R. M., Sarott, R. C., Ganzoni, R. L., et al. (2023). Platform reagents enable synthesis of ligand-directed covalent probes: study of cannabinoid receptor 2 in live cells. *J. Am. Chem. Soc.* 145 (28), 15094–15108. doi:10.1021/jacs.2c13629
- Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., et al. (2023). Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years. *Pharmacol. Rev.* 75 (5), 885–958. doi:10.1124/pharmrev.122.000600
- Mach, L., Omran, A., Bouma, J., Radetzi, S., Sykes, D. A., Guba, W., et al. (2024). Highly selective drug-derived fluorescent probes for the cannabinoid receptor type 1 (CB1R). *ChemRxiv Pre-Print*. doi:10.26434/chemrxiv-2024-xg4x8
- Martella, A., Sijben, H., Rufer, A. C., Grether, U., Fingerle, J., Ullmer, C., et al. (2017). A novel selective inverse agonist of the CB2 receptor as a radiolabeled tool compound for kinetic binding studies. *Mol. Pharmacol.* 92 (4), 389–400. doi:10.1124/mol.117.108605
- Moreira, F. A., and Crippa, J. A. S. (2009). The psychiatric side-effects of rimonabant. *Rev. Bras. Psiquiatr.* 31 (2), 145–153. doi:10.1590/s1516-44462009000200012
- Motulsky, H., and Neubig, R. (2002). Analyzing radioligand binding data. *Curr. Protoc. Neurosci.* 7. doi:10.1002/0471142301.ns0705s19
- Motulsky, H. J., and Christopoulos, A. (2004). *Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting*. Oxford University Press.
- Motulsky, H. J., and Mahan, L. C. (1984). The kinetics of competitive radioligand binding predicted by the law of mass action. *Mol. Pharmacol.* 25 (1), 1–9. doi:10.1016/s0026-895x(25)15016-5
- Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 365 (6441), 61–65. doi:10.1038/365061a0
- Muppidi, A., Lee, S. J., Hsu, C.-H., Zou, H., Lee, C., Pflimlin, E., et al. (2018). Design and synthesis of potent, long-acting lipidated relaxin-2 analogs. *Bioconjugate Chem.* 30 (1), 83–89. doi:10.1021/acs.bioconjugchem.8b00764
- Navarro, G., Morales, P., Rodríguez-Cueto, C., Fernández-Ruiz, J., Jagerovic, N., and Franco, R. (2016). Targeting cannabinoid CB2 receptors in the central nervous system. Medical chemistry approaches with focus on neurodegenerative disorders. *Front. Neurosci.* 10, 406. doi:10.3389/fnins.2016.00406
- Navarro, G., Sotelo, E., Raich, I., Loza, M. I., Brea, J., and Majellaro, M. (2023). A robust and efficient FRET-based assay for cannabinoid receptor ligands discovery. *Molecules* 28 (24), 8107. doi:10.3390/molecules28248107
- Pacher, P., Bátkai, S., and Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol. Rev.* 58 (3), 389–462. doi:10.1124/pr.58.3.2
- Papahadjis, D. P., Nahmias, V. R., Andreou, T., Fan, P., and Makriyannis, A. (2006). Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids. *Bioorg. and Med. Chem. Lett.* 16 (6), 1616–1620. doi:10.1016/j.bmcl.2005.12.026
- Raich, I., Rivas-Santisteban, R., Lillo, A., Lillo, J., Reyes-Resina, I., Nadal, X., et al. (2021). Similarities and differences upon binding of naturally occurring Δ^9 -tetrahydrocannabinol-derivatives to cannabinoid CB1 and CB2 receptors. *Pharmacol. Res.* 174, 105970. doi:10.1016/j.phrs.2021.105970
- Ramsey, S. J., Atkins, N. J., Fish, R., and van der Graaf, P. H. (2011). Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors *in vitro* and *in vivo*. *Br. J. Pharmacol.* 164 (3), 992–1007. doi:10.1111/j.1476-5381.2011.01390.x
- Ryberg, E., Vu, H. K., Larsson, N., Groblewski, T., Hjorth, S., Elebring, T., et al. (2005). Identification and characterisation of a novel splice variant of the human CB1 receptor. *FEBS Lett.* 579 (1), 259–264. doi:10.1016/j.febslet.2004.11.085
- Sarott, R. C., Westphal, M. V., Pfaff, P., Korn, C., Sykes, D. A., Gazzi, T., et al. (2020). Development of high-specificity fluorescent probes to enable cannabinoid type 2 receptor studies in living cells. *J. Am. Chem. Soc.* 142 (40), 16953–16964. doi:10.1021/jacs.0c05587
- Schiele, F., Ayaz, P., and Fernandez-Montalvan, A. (2015). A universal homogeneous assay for high-throughput determination of binding kinetics. *Anal. Biochem.* 468, 42–49. doi:10.1016/j.ab.2014.09.007
- Schihada, H., Shekhani, R., and Schulte, G. (2021). Quantitative assessment of constitutive G protein-coupled receptor activity with BRET-based G protein biosensors. *Sci. Signal.* 14 (699), eabf1653. doi:10.1126/scisignal.abf1653
- Scott-Dennis, M., Rafani, F. A., Yi, Y., Perera, T., Harwood, C. R., Guba, W., et al. (2023). Development of a membrane-based Gi-CASE biosensor assay for profiling compounds at cannabinoid receptors. *Front. Pharmacol.* 14, 1158091. doi:10.3389/fphar.2023.1158091
- Soave, M., Briddon, S. J., Hill, S. J., and Stoddart, L. A. (2020). Fluorescent ligands: bringing light to emerging GPCR paradigms. *Br. J. Pharmacol.* 177 (5), 978–991. doi:10.1111/bph.14953
- Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., et al. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. *Nat. Commun.* 8 (1), 13958. doi:10.1038/ncomms13958
- Soethoudt, M., Hoorens, M. W. H., Doelman, W., Martella, A., van der Stelt, M., and Heitman, L. H. (2018). Structure-kinetic relationship studies of cannabinoid CB2 receptor agonists reveal substituent-specific lipophilic effects on residence time. *Biochem. Pharmacol.* 152, 129–142. doi:10.1016/j.bcp.2018.03.018
- Sykes, D. A., Dowling, M. R., and Charlton, S. J. (2010). Measuring receptor target coverage: a radioligand competition binding protocol for assessing the association and dissociation rates of unlabeled compounds. *Curr. Protoc. Pharmacol.* 50 (1). doi:10.1002/0471141755.ph0914s50
- Sykes, D. A., Dowling, M. R., Leighton-Davies, J., Kent, T. C., Fawcett, L., Renard, E., et al. (2012). The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. *J. Pharmacol. Exp. Ther.* 343 (2), 520–528. doi:10.1124/jpet.112.194456
- Sykes, D. A., Jain, P., and Charlton, S. J. (2019). Investigating the influence of tracer kinetics on competition-kinetic association binding assays: identifying the optimal conditions for assessing the kinetics of low-affinity compounds. *Mol. Pharmacol.* 96 (3), 378–392. doi:10.1124/mol.119.116764
- Sykes, D. A., Jimenez-Roses, M., Reilly, J., Fairhurst, R. A., Charlton, S. J., and Veprintsev, D. B. (2022). Exploring the kinetic selectivity of drugs targeting the β_1 -adrenoceptor. *Pharmacol. Res. Perspect.* 10 (4), e00978. doi:10.1002/prp2.978
- Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., et al. (2017). Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. *Nat. Commun.* 8 (1), 763. doi:10.1038/s41467-017-00716-z
- Sykes, D. A., Stoddart, L. A., Kilpatrick, L. E., and Hill, S. J. (2019). Binding kinetics of ligands acting at GPCRs. *Mol. Cell. Endocrinol.* 485, 9–19. doi:10.1016/j.mce.2019.01.018
- Thakur, G. A., Duclos, R. I., and Makriyannis, A. (2005). Natural cannabinoids: templates for drug discovery. *Life Sci.* 78 (5), 454–466. doi:10.1016/j.lfs.2005.09.014
- Terry, G. E., Liow, J. S., Zoghbi, S. S., Hirvonen, J., Farris, A. G., Lerner, A., et al. (2009). Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. *Neuroimage* 48 (2), 362–370. doi:10.1016/j.neuroimage.2009.06.059
- Tresadern, G., Bartolome, J. M., Macdonald, G. J., and Langlois, X. (2011). Molecular properties affecting fast dissociation from the D2 receptor. *Bioorg. and Med. Chem.* 19 (7), 2231–2241. doi:10.1016/j.bmc.2011.02.033
- Uchiyama, S., Takehira, K., Kohtani, S., Imai, K., Nakagaki, R., Tobita, S., et al. (2003). Fluorescence on-off switching mechanism of benzofurazans. *Org. and Biomol. Chem.* 1 (6), 1067–1072. doi:10.1039/b212575g
- Vauquelin, G. (2016). Effects of target binding kinetics on *in vivo* drug efficacy: koff, kon and rebinding. *Br. J. Pharmacol.* 173 (15), 2319–2334. doi:10.1111/bph.13504
- Vuic, B., Milos, T., Tudor, L., Konjevod, M., Nikolac Perkovic, M., Jazvinskak Jembrek, M., et al. (2022). Cannabinoid CB2 receptors in neurodegenerative proteinopathies: new insights and therapeutic potential. *Biomedicines* 10 (12), 3000. doi:10.3390/biomedicines10123000
- Westphal, M. V., Sarott, R. C., Zirwes, E. A., Osterwald, A., Guba, W., Ullmer, C., et al. (2020). Highly selective, amine-derived cannabinoid receptor 2 probes. *Chem. – A Eur. J.* 26 (6), 1380–1387. doi:10.1002/chem.201904584
- Xia, L., de Vries, H., Lenselink, E. B., Louvel, J., Waring, M. J., Cheng, L., et al. (2017). Structure-affinity relationships and structure-kinetic relationships of 1,2-Diarylimidazol-4-carboxamide derivatives as human cannabinoid 1 receptor antagonists. *J. Med. Chem.* 60 (23), 9545–9564. doi:10.1021/acs.jmedchem.7b00861
- Xia, L., de Vries, H., Yang, X., Lenselink, E. B., Kyrizaki, A., Barth, F., et al. (2018). Kinetics of human cannabinoid 1 (CB1) receptor antagonists: structure-kinetics relationships (SKR) and implications for insurmountable antagonism. *Biochem. Pharmacol.* 151, 166–179. doi:10.1016/j.bcp.2017.10.014
- Xiao, J. C., Jewell, J. P., Lin, L. S., Hagmann, W. K., Fong, T. M., and Shen, C.-P. (2008). Similar *in vitro* pharmacology of human cannabinoid CB1 receptor variants expressed in CHO cells. *Brain Res.* 1238, 36–43. doi:10.1016/j.brainres.2008.08.027
- Zuadi, A. W. (2006). History of cannabis as a medicine: a review. *Rev. Bras. Psiquiatr.* 28 (2), 153–157. doi:10.1590/s1516-44462006000200015
- Zuadi, A. W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Braz. J. Psychiatry* 30 (3), 271–280. doi:10.1590/s1516-44462008000300015